The upcoming report from Gilead Sciences (GILD) is expected to reveal quarterly earnings of $1.89 per share, indicating an increase of 4.4% compared to the year-ago period. Analysts forecast revenues ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

In the latest close session, Gilead Sciences (GILD) was up +1.55% at $130.84. This change outpaced the S&P 500's 1.02% gain on the day. Elsewhere, the Dow saw an upswing of 1.62%, while the tech-heavy ...

Gilead (GILD) wraps up $7.8B Arcellx deal, gaining anito-cel therapy. Stock tests key support at $128 with oversold RSI ...

Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Trevor Young’s Substack. In this ...

Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the September 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

This morning a "Potential Dividend Run Alert" went out for Gilead Sciences Inc (NASD: GILD), at our DividendChannel.com Dividend Alerts service (a free email alerts feature). Let's look at the ...

We recently published 10 Stocks with Eye-Popping Gains; 5 Jump to New Highs. Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best-performing stocks on Friday. Gilead Sciences jumped to a new ...

Gilead Sciences ( GILD) shares snapped a six-session losing streak, closing 0.56% higher at $133.64 on Thursday. The biopharmaceutical company began its downward trend on April 15, and the stock lost ...